Transdermal Patch Bioequivalence Studies
A patch has to match the reference twice — in the bloodstream and on the skin. Transdermal BE programs pair pharmacokinetics with adhesion, irritation, and residual drug endpoints no oral study ever needs.
TDS Program
Scoring Scale
Methods
Facility
How Bioequivalence Works for Transdermal Systems
A transdermal delivery system (TDS) is judged on more than plasma concentrations. For a generic patch, the US FDA typically expects three in vivo demonstrations: a pharmacokinetic bioequivalence study, an adhesion study showing the patch stays attached as well as the reference through the full wear period, and a skin irritation and sensitization study showing it is no harsher on the skin.
The PK study itself is unusual. Wear periods run from 24 hours to 7 days, so sampling schedules stretch across the entire application — parameters such as AUC over 72 or 168 hours matter — and confinement has to accommodate continuous wear, timed adhesion scoring, and controlled removal. Afterward the science moves to the laboratory: residual drug in worn patches is quantified to establish how much of the loaded dose was actually delivered.
We run TDS programs at our DCGI-mandated centre in Pune: extended-confinement clinical conduct with trained adhesion scoring, LC-MS/MS bioanalysis of plasma samples, and worn-patch residual drug analysis — one facility carrying all three endpoint families of a transdermal submission.
In vivo scoring of attached patch surface area at defined intervals through wear, on FDA’s 0–4 scale where 0 means at least 90% adhered and 4 means detached. The test patch must perform no worse than the reference.
Quantifying the drug remaining in patches after wear. Comparable residuals support equivalent delivered dose; excessive residual raises both efficacy and disposal-safety questions.
Oral BE vs Transdermal Patch BE
The 80.00–125.00% statistics carry over — everything around them multiplies.
| Aspect | Oral Tablet BE | Transdermal Patch BE |
|---|---|---|
| Endpoint families | Pharmacokinetics only | Pharmacokinetics plus adhesion, irritation, and sensitization |
| Dosing event | Swallowed once per period | Continuous wear for 24 hours to 7 days per period |
| Sampling window | Hours around Cmax and elimination | The full wear period and beyond — AUC to 72 or 168 hours |
| Extra laboratory work | None | Residual drug quantitation in every worn patch |
| Skin endpoints | Not applicable | Adhesion scored on the 0–4 scale; irritation and sensitization compared against reference |
| Acceptance criteria | 90% CI of Cmax & AUC within 80.00–125.00% | Same PK criteria, plus non-inferior adhesion and comparable skin tolerance |
The Five Demonstrations of a TDS Program
PK Bioequivalence
Crossover study across full wear periods; 90% CI of Cmax and AUC within 80.00–125.00%.
Adhesion Performance
Scored at defined intervals through wear; the test patch must be non-inferior to the reference.
Skin Irritation
Repeated-application scoring to show the test patch irritates no more than the reference.
Sensitization
Induction, rest, and challenge phases to rule out a higher allergic potential than the reference.
Residual Drug
Worn patches assayed for remaining drug to compare delivered dose between products.
Transdermal BE Program Flow
- 01
Guidance Mapping
The product-specific guidance decides which studies, endpoints, and wear conditions apply — the program is designed from it, not adapted to it later.
- 02
Ethics & Protocols
PK, adhesion, and irritation/sensitization protocols — combined where the guidance permits — cleared through the ethics committee.
- 03
Clinical Wear Periods
Confined conduct with controlled application sites, timed adhesion scoring, and PK sampling through wear and after removal.
- 04
Laboratory Analysis
Plasma LC-MS/MS on a validated method, plus residual drug quantitation of the collected worn patches.
- 05
Integrated Reporting
PK statistics, adhesion non-inferiority, skin tolerance, and residuals reported as one coherent submission package.
Why Sponsors Choose Us for Transdermal Patch BE
- PK, adhesion, and skin-tolerance endpoints handled in one program
- Extended-confinement conduct built for multi-day wear periods
- Trained, consistent adhesion scoring on the FDA 0–4 scale
- Residual drug analysis of worn patches in our LC-MS/MS laboratory
- DCGI-mandated, ANVISA-approved facility in Pune
- Programs mapped directly to US FDA product-specific guidances
Transdermal Patch BE — Frequently Asked Questions
1. How is bioequivalence established for transdermal patches?
2. What is a patch adhesion study?
3. Why is residual drug analysis required for transdermal products?
4. How long do PK sampling schedules run for patch studies?
5. What are skin irritation and sensitization studies?
6. Can the PK and adhesion studies be combined?
More BA/BE Studies Services
Every study type under one roof — explore the rest of our ba/be studies capabilities.
Pilot BE Studies
Small, fast studies that measure formulation variability before you commit to a pivotal trial.
Fed & Fasting BE
Food-effect and fed BE studies that show your product performs against the reference in both dosing states.
Patient BE Studies
BE studies in patients when healthy-volunteer dosing is unsafe — cytotoxic, oncology, and high-risk products.
Biosimilar PK Studies
Comparative pharmacokinetic similarity studies for biosimilars, backed by large-molecule LC-MS/MS.
Population BE
Designs and statistics for when average bioequivalence alone cannot answer the prescribability question.
Postmenopausal Studies
Special-population BA/BE studies in postmenopausal women for hormone and women’s-health products.
Nasal Spray BE
Device-based BE combining in vitro performance testing with in vivo PK under a weight-of-evidence approach.
Bioanalytical Services
LC-MS/MS method development, ICH M10 validation, and study sample analysis — the lab behind every study.
Discuss Your Transdermal Patch BE Requirement
Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.